Share on StockTwits

Pfenex (NASDAQ:PFNX) issued its quarterly earnings data on Tuesday. The company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $1.52, Analyst RN reports.

PFNX has been the subject of a number of recent research reports. Analysts at JMP Securities initiated coverage on shares of Pfenex in a research note on Monday, August 18th. They set an “outperform” rating and a $15.00 price target on the stock. On a related note, analysts at William Blair initiated coverage on shares of Pfenex in a research note on Monday, August 18th. They set an “outperform” rating and a $4.30 price target on the stock. Finally, analysts at Mizuho initiated coverage on shares of Pfenex in a research note on Monday, August 18th. They set a “buy” rating and a $12.00 price target on the stock.

Shares of Pfenex (NASDAQ:PFNX) opened at 6.45 on Tuesday. Pfenex has a 1-year low of $5.28 and a 1-year high of $6.59. The stock’s 50-day moving average is $6.12 and its 200-day moving average is $6.12. The company’s market cap is $124.1 million.

Pfenex Inc is a clinical-stage biotechnology company. The Company engaged in the development of difficult to manufacture and proteins, initially focused on biosimilar therapeutics (NASDAQ:PFNX).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.